9KB6 image
Deposition Date 2024-10-30
Release Date 2025-10-15
Last Version Date 2025-10-15
Entry Detail
PDB ID:
9KB6
Title:
Cryo-EM structure of LGR4
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.53 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Leucine-rich repeat-containing G-protein coupled receptor 4
Gene (Uniprot):LGR4
Chain IDs:A
Chain Length:845
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Structural insights into Wnt/ beta-catenin signaling regulation by LGR4, R-spondin, and ZNRF3.
Nat Commun 16 8337 8337 (2025)
PMID: 41034211 DOI: 10.1038/s41467-025-64129-z

Abstact

Leucine-rich repeat-containing G protein-coupled receptor 4 (LGR4) plays a critical role in regulating the wingless-related integration site (Wnt) signaling pathway and is essential for organ development and carcinogenesis. LGR4, along with its ligand R-spondin (RSPO), potentiates Wnt/β-catenin signaling by recruiting its signaling suppressor, E3 ligase Zinc and Ring Finger 3 (ZNRF3), and inducing its membrane clearance. However, detailed mechanisms underlying this process remain unknown. In this study, we present the cryo-electron microscopy structures of human LGR4, the LGR4-RSPO2 and LGR4-RSPO2-ZNRF3 complexes. Upon RSPO2 binding, LGR4 undergoes no significant conformational changes in its transmembrane and extracellular domain structures or their relative orientations. LGR4, RSPO2, and ZNRF3 assemble into a 2:2:2 complex with the ZNRF3 dimer enclosed at the center. This ternary arrangement and forced dimerization of ZNRF3 likely underpin how LGR4 and RSPO2 potentiate Wnt/β-catenin signaling by sequestering ZNRF3 from Wnt receptors and facilitating its auto-inactivation. This study provides a structural basis for understanding the regulatory mechanism of Wnt/β-catenin signaling through the LGR4-RSPO2-ZNRF3 pathway and may offer opportunities for future drug development targeting this axis.

Legend

Protein

Chemical

Disease

Primary Citation of related structures